Reinhard M. Berner
Advanced in Streptococcal Group A Infection

Reinhard M. Berner

Dresden, SN, DE 
Clinical Trials:Currently Recruiting for 2 Trials
Advanced in Streptococcal Group A Infection
Dresden, SN, DE 
OverviewLocationsClinical Research

Overview

Reinhard Berner practices in Dresden, Germany. Mr. Berner is rated as an Advanced expert by MediFind in the treatment of Streptococcal Group A Infection. His top areas of expertise are Streptococcal Group B Infection, Streptococcal Group A Infection, Severe Acute Respiratory Syndrome (SARS), and Strep Throat.

His clinical research consists of co-authoring 163 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 14 articles in the study of Streptococcal Group A Infection.

Gender
Male

Locations

Dresden, SN, Germany
Other Locations
Berlin, BE, Germany
Freiburg, BW, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Open-Label, Randomized Study With a Tocilizumab Reference Arm to Evaluate Safety, Efficacy and Pharmacokinetics of Baricitinib in Children From 1 to Less Than 18 Years of Age With Systemic Juvenile Idiopathic Arthritis.
Open-Label, Randomized Study With a Tocilizumab Reference Arm to Evaluate Safety, Efficacy and Pharmacokinetics of Baricitinib in Children From 1 to Less Than 18 Years of Age With Systemic Juvenile Idiopathic Arthritis.
Enrollment Status: Recruiting
Publish Date: October 09, 2025
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA)
A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA)
Enrollment Status: Recruiting
Publish Date: September 23, 2025
Intervention Type: Drug
Study Drug: Baricitnib
Study Phase: Phase 3

162 Total Publications

S3-Guideline on Measures for the Prevention and Control of SARS-CoV-2 Transmission in Schools.
S3-Guideline on Measures for the Prevention and Control of SARS-CoV-2 Transmission in Schools.
Journal: Klinische Padiatrie
Published: July 10, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Berner's expertise for a condition
ConditionClose
    View All 28 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile